When to Start Jardiance (Empagliflozin) in Diabetic Patients
Start empagliflozin 10 mg once daily immediately upon diagnosis of type 2 diabetes if the patient has established cardiovascular disease, heart failure, or chronic kidney disease with eGFR ≥20 mL/min/1.73 m², regardless of HbA1c level or current metformin use. 1, 2
Primary Indications for Starting Empagliflozin
1. Established Cardiovascular Disease (Highest Priority)
Start empagliflozin in any adult with type 2 diabetes who has:
- Prior myocardial infarction
- Acute coronary syndrome
- Coronary revascularization
- Stroke
- Peripheral artery disease
- Stable or unstable angina
This indication takes precedence over glycemic control considerations because empagliflozin reduces cardiovascular death by 38% (HR 0.62) and all-cause mortality by 32% (HR 0.68) in this population 1. The cardiovascular benefit occurs independently of glucose-lowering effects and is present even when HbA1c is well-controlled 2.
2. Heart Failure (Any Ejection Fraction)
Initiate empagliflozin 10 mg daily in patients with:
- Heart failure with reduced ejection fraction (any NYHA class)
- Heart failure with preserved ejection fraction (LVEF >40%)
- With or without diabetes 3, 4
The FDA has approved empagliflozin specifically to reduce cardiovascular death and heart failure hospitalization in adults with heart failure, making this a primary indication rather than a secondary consideration 5.
3. Chronic Kidney Disease
Start empagliflozin when eGFR ≥20 mL/min/1.73 m² in patients with:
- Albuminuria (UACR ≥200 mg/g): Strong recommendation 6, 7
- eGFR 20-45 mL/min/1.73 m² with UACR <200 mg/g: Reasonable to initiate 7
- Diabetic kidney disease with any degree of albuminuria 8
The 2022 ADA-KDIGO consensus specifically recommends SGLT2 inhibitors for patients with eGFR ≥20 mL/min/1.73 m² to reduce CKD progression and cardiovascular events 6.
4. High Cardiovascular Risk Without Established Disease
Consider empagliflozin in patients ≥50 years with multiple risk factors:
- Hypertension
- Dyslipidemia
- Smoking
- Obesity
- End-organ damage (left ventricular hypertrophy, retinopathy) 2
Glycemic Control Indication
For patients without cardiovascular disease, heart failure, or CKD:
- Start empagliflozin as second-line therapy after metformin if HbA1c remains ≥7% 1
- Can be used as monotherapy if metformin is contraindicated or not tolerated 5
- Initial dose: 10 mg once daily; may increase to 25 mg if additional glycemic control needed 5
Important caveat: For glycemic control alone, empagliflozin is not recommended when eGFR <30 mL/min/1.73 m² as it becomes ineffective for glucose lowering 5. However, it can still be initiated for cardiovascular/renal protection down to eGFR 20 mL/min/1.73 m² 6.
Dosing by eGFR
| eGFR (mL/min/1.73 m²) | Recommendation |
|---|---|
| ≥45 | Start 10 mg; may increase to 25 mg for glycemic control [2,5] |
| 30-44 | Start 10 mg; do not increase dose [2] |
| 20-29 | Start 10 mg for CV/renal protection only (not for glycemic control) [6,7] |
| <20 | Insufficient data; contraindicated if on dialysis [5] |
Critical Pre-Initiation Assessments
Before starting empagliflozin, check:
- eGFR - Must be ≥20 mL/min/1.73 m² (≥30 for glycemic indication)
- Volume status - Correct volume depletion first, especially in elderly or those on diuretics 2, 6
- Pregnancy status - Contraindicated in pregnancy/breastfeeding 2
- History of amputation - Use caution with prior amputation, severe peripheral vascular disease, or active diabetic foot ulcers 1
Medication Adjustments at Initiation
- Insulin or sulfonylureas: Reduce dose by ~20% to prevent hypoglycemia 2, 6
- Diuretics: Consider reducing dose in patients at risk for volume depletion 6
- Continue metformin - Most trial participants were on metformin at baseline 1
Common Pitfalls to Avoid
Waiting for HbA1c to rise: Don't delay initiation in patients with established ASCVD or heart failure just because HbA1c is controlled. The mortality benefit is independent of glucose lowering 1, 2.
Stopping at low eGFR: Continue empagliflozin even if eGFR falls below initiation threshold during treatment, unless dialysis is started 6, 7.
Discontinuing during hospitalization: Can be safely continued during heart failure hospitalization once hemodynamically stable 4.
Forgetting sick day rules: Instruct patients to hold empagliflozin during acute illness, prolonged fasting, or surgery to reduce ketoacidosis risk 2, 6, 5.
Safety Monitoring
- Genital mycotic infections: Counsel on hygiene; occurs in 10-15% of women, less in men 2, 3
- Euglycemic DKA: Rare but serious; maintain at least low-dose insulin in insulin-requiring patients 6, 5
- eGFR dip: Expect reversible 3-5 mL/min decline in first 4 weeks; this is not an indication to stop 6, 7
- Volume depletion: Monitor blood pressure, especially in elderly or those on diuretics 2, 6